

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and Waiver under 18 U.S.C. §208(b)(3)

Peter Gross, M.D.

**Committees:** Joint meeting of the Dermatologic and Ophthalmic Drugs and the Drug Safety and Risk Management Advisory Committees

**Meeting Dates:** August 1, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the briefing on iPLEDGE, the risk management program for isotretinoin products; Presentations will provide updates on risk management activities for isotretinoin since the full implementation of iPLEDGE on March 1, 2006, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3) .

Type of Interest	Nature	Magnitude
Speaker's Bureau	Affected Firm	Less than \$10,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

PSI  
Signature of SGE

6/26/07  
Date